Neurocognitive domains of impulsivity in Parkinson’s disease (PD) and the effects of dopaminergic replacement therapy (DRT)
Objective: To investigate whether 3 different domains of impulsive behavior(reactive, proactive and cognitive) are differentially affected in medicated PD as compared with healthy controls. We…The differentiated treatment of Parkinson’s disease in patients with concomitant diabetes mellitus(DM) type 2
Objective: To study the state of lipid metabolism in PD patients with concomitant type 2 diabetes with different glucose tolerance and the influence of the…Substantial motor and non-motor symptoms in children and adults with classical galactosemia and organic acidurias
Objective: To investigate the prevalence of movement disorders (MDs), their impact on quality of life (QoL) and accompanying non-motor symptoms in patients with classical galactosemia…Safety of nelotanserin in a randomized placebo-controlled phase 2 study
Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…Speed and severity of toxicity induced by pre-formed α-synuclein fibrils in rat brain is enhanced by α-synuclein overexpression
Objective: To develop a physiologically relevant model of PD. Background: Intracerebral injection of pre-formed α-synuclein fibrils has emerged as an interesting tool to induce PD-like…Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia
Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…Prevalence of impulse control disorders among adult Filipino patients with idiopathic Parkinson’s disease seen at a tertiary center in Manila
Objective: (1) To determine the prevalence and severity of Impulse Control Disorders (ICDs) in adult Filipino patients with idiopathic Parkinson's disease seen at a tertiary…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls
Objective: To assess patients with Parkinson's disease (PwPD) impulsive-compulsive behaviors (ICBs) prevalence compared to healthy controls (HCs) group, to analyze PD clinical features, ICBs risk…Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats
Objective: In the present study potential neuroprotective effects of curcumin were tested to determine if they could help to minimize microglia–mediated damage in single intranigral…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.